The NJ Mass Spectrometry Discussion Group presents the March 2013 Meeting on Tuesday, March 12, 2013 at the Holiday Inn Somerset-Bridgewater, 195 Davidson Ave, Somerset NJ 08873. Sponsored by Bruker & ImaBiotech SA.
Attendance is free of charge, compliments of our sponsors!
Please register here.
Vice President, Chemical and Applied Markets, Bruker
“Peptide Quantitation at Analytical Flow Rates – Challenges with Ionization at High-flow Rates”
CEO / CSO ImaBiotech, ImaBiotech SA
“Label-free MS imaging from drug discovery to preclinical development
5:30 pm Social and registration
6:15 pm Complimentary dinner
7:00 pm Welcome and opening remarks
7:05 pm Rohan Thakur
8:00 pm Jonathan Stauber
8:55 pm Closing remarks
Abstract for Jonathan Stauber: Mass Spectrometry Imaging (MSI) has become a common technique to localize molecules directly on the surface of biological tissues without labeling. Recently, ImaBiotech performed quantitative studies by developing and using dedicated software (Quantinetix) and combined the quantitative MS imaging with Metabolomics studies with High Resolution Mass Spectrometry Imaging. This presentation shows the benefits of MS imaging applications in different therapeutic areas (CNS, Oncology, Ophthalmology) from discovery to preclinical development stages.
Abstract for Rohan Thakur: Targeted quantification of peptides is now becoming routine. The challenges with micro-flow/nano-flow work are well understood and fall short when compared to the method robustness demonstrated by small molecule analysis over the past 20 years. To get the required robustness for peptide analysis, one can use higher flow rates with UHPLC and traditional heated electrospray settings – the issue then becomes ensuring optimal ionization and avoiding thermal breakdown before the ionization step in modern high flow heated electrospray methods. This presentation will show the use of cutting-edge material science technology to provide optimal ionization of peptides at analytical flow rates, especially thermally labile components.